ABSTRACT
BACKGROUND: Patients with sickle cell disease (SCD), an inherited haemoglobinopathy, have increased risk of malaria, at least in part due to impaired splenic function. Infection with Plasmodium falciparum in SCD patients can trigger painful vaso-occlusive crisis, increase the severity of anaemia, and contribute to early childhood mortality. CASE PRESENTATION: A 17 year-old Tanzanian male with known SCD was admitted to Muhimbili National Hospital, a tertiary referral centre in Dar-es-Salaam, following an attack of malaria. From 2004 to 2007 the patient had lived in USA, and from 2010 to 2016 in France where, on account of hypersplenism and episodes of splenic sequestrations, in 2014 the spleen was removed. After appropriate clinical and laboratory assessment the patient was re-started on hydroxyurea; and anti-malarial-prophylaxis with proguanil was instituted. The patient has remained well and malaria-free for the following 15 months. CONCLUSION: SCD patients are highly vulnerable to malaria infection, and impaired splenic function is a feature of SCD patients, even in those who still anatomically have a spleen. This patient had a surgical splenectomy and, in addition, had probably lost some of the acquired malaria-immunity by having lived for several years in malaria-free areas. This patient is a compelling reminder that long-term anti-malarial prophylaxis should be offered to all patients with SCD who live in malaria-endemic areas.
Subject(s)
Anemia, Sickle Cell/complications , Antimalarials/administration & dosage , Antisickling Agents/administration & dosage , Hydroxyurea/administration & dosage , Malaria, Falciparum/drug therapy , Proguanil/administration & dosage , Adolescent , Humans , Malaria, Falciparum/parasitology , Male , Splenectomy , TanzaniaABSTRACT
Loop-mediated isothermal amplification (LAMP) is a rapid molecular technique that has been introduced into malaria diagnosis. The test is easy to perform and offers high sensitivity. We report a 53-year-old male patient who was hospitalized with fever attacks, chills, and headache caused 9 months after returning from Africa. During his stay in Africa, he used malaria chemoprophylaxis. Microscopy of thin and thick blood films and rapid diagnostic antigen testing remained negative for three times. The EDTA blood samples were tested using the Meridian illumigene® malaria LAMP assay that gave a positive result for Plasmodium spp. Diagnosis of malaria was subsequently specified as P. ovale infection by real-time PCR. Ovale malaria often manifests with delay and low parasitemia. The patient was treated with atovaquone-proguanil, followed by primaquine for prophylaxis of relapse. This case illustrates the usefulness of the illumigene® malaria LAMP assay for initial screening of malaria parasites.
Subject(s)
Malaria/diagnosis , Molecular Diagnostic Techniques/methods , Nucleic Acid Amplification Techniques/methods , Plasmodium ovale/isolation & purification , Travel-Related Illness , Africa, Western , Antimalarials/administration & dosage , Atovaquone/administration & dosage , Drug Combinations , Germany , Humans , Malaria/drug therapy , Male , Middle Aged , Plasmodium ovale/genetics , Primaquine , Proguanil/administration & dosage , Sensitivity and SpecificityABSTRACT
AIMS: Vonoprazan, a new class of potassium-competitive proton pump inhibitors has been found to attenuate the antiplatelet function of clopidogrel in a recent clinical study, despite weak in vitro activity against CYP2C19. To elucidate the mechanism of this interaction, the present study investigated the effects of esomeprazole and vonoprazan on the pharmacokinetics of proguanil, a CYP2C19 substrate. METHODS: Seven healthy male volunteers (CYP2C19 extensive metabolizers) received a single oral administration of 100 mg proguanil/250 mg atovaquone (control phase), oral esomeprazole (20 mg) for 5 days followed by proguanil/atovaquone (esomeprazole phase) and oral vonoprazan (20 mg) for 5 days followed by proguanil/atovaquone (vonoprazan phase). Concentrations of proguanil and its metabolite, cycloguanil, in plasma and urine in each phase were determined using liquid chromatography-tandem mass spectrometry. RESULTS: Coadministration with proton pump inhibitors resulted in increase and decrease in the area under the plasma concentration-time curve (AUC) of proguanil and cycloguanil, respectively, significantly reducing their AUC ratio (cycloguanil/proguanil) to 0.317-fold (95% confidence interval [CI] 0.256-0.379) and 0.507-fold (95% CI 0.409-0.605) in esomeprazole phase and vonoprazan phase, respectively. Esomeprazole and vonoprazan also significantly reduced the apparent formation clearance (cumulative amount of cycloguanil in urine divided by AUC of proguanil) to 0.324-fold (95% CI 0.212-0.436) and 0.433-fold (95% CI 0.355-0.511), respectively, without significant changes in renal clearance of proguanil and cycloguanil. CONCLUSIONS: Although further studies are needed, both esomeprazole and vonoprazan potentially inhibit CYP2C19 at clinical doses, suggesting caution in the coadministration of these drugs with CYP2C19 substrates.
Subject(s)
Esomeprazole/pharmacology , Proguanil/pharmacokinetics , Proton Pump Inhibitors/pharmacology , Pyrroles/pharmacology , Sulfonamides/pharmacology , Adult , Area Under Curve , Atovaquone/administration & dosage , Chromatography, Liquid , Cytochrome P-450 CYP2C19/metabolism , Drug Combinations , Esomeprazole/administration & dosage , Humans , Male , Proguanil/administration & dosage , Proton Pump Inhibitors/administration & dosage , Pyrroles/administration & dosage , Sulfonamides/administration & dosage , Tandem Mass Spectrometry , Triazines/pharmacokinetics , Young AdultABSTRACT
BACKGROUND: Poor compliance with chemoprophylaxis is a major contributing factor to the risk of malaria in travelers. Pre-travel chemoprophylaxis may improve compliance by enabling "drug-free holidays." The standard treatment dose of atovaquone/proguanil (250 mg/100 mg, 4 tablets/day for 3 days) provides protection against malaria for at least 4 weeks, and could therefore potentially be used for pre-travel chemoprophylaxis. In this study, we assessed the compliance, tolerability, and acceptability of the 3-day atovaquone/proguanil schedule for malarial chemoprophylaxis. METHODS: Two hundred thirty-three participants were recruited from 4 specialized travel medicine clinics in Australia. Adults traveling to malaria-endemic areas with low/medium risk for ≤4 weeks were enrolled and prescribed the 3-day schedule of atovaquone/proguanil, completed at least 1 day before departure. Questionnaires were used to collect data on demographics, travel destination, medication compliance, side effects, and reasons for choosing the 3-day schedule. RESULTS: Overall, 97.7% of participants complied with the 3-day schedule. Although side effects were reported in 43.3% of the participants, these were well tolerated, and mainly occurred during the first and second days. None of the participants developed malaria. The main reasons for choosing the 3-day schedule over standard chemoprophylaxis options were that it was easier to remember (72.1%), required taking fewer tablets (54.0%), and to help scientific research (54.0%). CONCLUSIONS: The 3-day atovaquone/proguanil schedule had an impressively high compliance rate, and was well tolerated and accepted by travelers. Further studies are required to assess the effectiveness of this schedule for chemoprophylaxis in travelers. CLINICAL TRIALS REGISTRATION: ACTRN12616000640404.
Subject(s)
Antimalarials/administration & dosage , Atovaquone/administration & dosage , Malaria/prevention & control , Medication Adherence , Patient Acceptance of Health Care , Proguanil/administration & dosage , Travel , Adult , Aged , Aged, 80 and over , Australia , Chemoprevention/methods , Drug Administration Schedule , Drug Combinations , Drug Tolerance , Female , Holidays , Humans , Male , Middle Aged , Surveys and Questionnaires , Travel Medicine/methods , Young AdultABSTRACT
Malaria is a potentially life-threatening disease caused by infection with the Plasmodium protozoa transmitted by an infective female Anopheles mosquito. Despite successful control programs in many countries, malaria remains to be a major disease burden worldwide, with approximately 584,000 deaths annually. The incidence of the disease and responsible species may differ due to increased human movements between countries. Plasmodium falciparum infection carries a poor prognosis with a high mortality if untreated, but it has an excellent prognosis if diagnosed early and treated appropriately. In the present study, we described a patient diagnosed with falciparum malaria and treated with atovaquone-proguanil who had a history of traveling to Uganda.
Subject(s)
Antimalarials/therapeutic use , Atovaquone/therapeutic use , Malaria, Falciparum/diagnosis , Proguanil/therapeutic use , Adult , Animals , Antimalarials/administration & dosage , Atovaquone/administration & dosage , Drug Combinations , Female , Humans , Malaria, Falciparum/drug therapy , Plasmodium falciparum/isolation & purification , Proguanil/administration & dosage , Recurrence , Travel , UgandaABSTRACT
Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To elucidate the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the U.S. Food and Drug Administration, World Health Organization, and European Medicines Agency guidelines, but data for permeability are inconclusive. Therefore, proguanil hydrochloride is conservatively classified as a BCS class 3 substance. In view of this information and the assessment of risks associated with a false positive decision, a BCS-based biowaiver approval procedure can be recommended for orally administered solid immediate release products containing proguanil hydrochloride, provided well-known excipients are used in usual amounts and provided the in vitro dissolution of the test and reference products is very rapid (85% or more are dissolved in 15 min at pH 1.2, 4.5, and 6.8) and is performed according to the current requirements for BCS-based biowaivers.
Subject(s)
Antimalarials/administration & dosage , Antimalarials/therapeutic use , Malaria/drug therapy , Proguanil/administration & dosage , Proguanil/therapeutic use , Administration, Oral , Animals , Antimalarials/chemistry , Antimalarials/pharmacokinetics , Dosage Forms , Excipients/chemistry , Humans , Proguanil/chemistry , Proguanil/pharmacokinetics , Solubility , Therapeutic EquivalencyABSTRACT
Compared with other plasmodium species which cause human malaria, Plasmodium malariae is considered to be relatively infrequent and milder, although recent reports indicate that its prevalence and impact have been under-estimated. A 23-month-old boy, born and previously living in a refugee camp in Liberia who presented with P. malariae 6 weeks after arrival in the USA, is reported. Despite ostensibly effective anti-malarial treatment with artemether/lumefantrine and two courses of hydrochloroquine, he experienced recurrent parasitaemia, refractory anaemia and splenomegaly over a 6-month period; the symptoms resolved after he received atovaquone/proguanil. It is hypothesised that the recrudescing clinical malaria in this case was related to the long pre-erythrocytic phase unique to P. malariae, and potentially also to a proportion of the parasites being drug-resistant.
Subject(s)
Antimalarials/administration & dosage , Communicable Diseases, Imported/diagnosis , Communicable Diseases, Imported/drug therapy , Emigrants and Immigrants , Malaria/diagnosis , Malaria/drug therapy , Plasmodium malariae/isolation & purification , Artemether, Lumefantrine Drug Combination/administration & dosage , Atovaquone/administration & dosage , Chloroquine/administration & dosage , Communicable Diseases, Imported/parasitology , Communicable Diseases, Imported/pathology , Drug Combinations , Humans , Infant , Liberia , Malaria/parasitology , Malaria/pathology , Male , Proguanil/administration & dosage , Recurrence , Treatment Outcome , United StatesABSTRACT
Background: Atovaquone-proguanil is considered causal prophylaxis (inhibition of liver-stage schizonts) for Plasmodium falciparum; however, its causal prophylactic efficacy for Plasmodium vivax is not known. Travelers returning to nonendemic areas provide a unique opportunity to study P. vivax prophylaxis. Methods: In a retrospective observational study, for 11 years, Israeli rafters who had traveled to the Omo River in Ethiopia, a highly malaria-endemic area, were followed for at least 1 year after their return. Malaria prophylaxis used during this period included mefloquine, doxycycline, primaquine, and atovaquone-proguanil. Prophylaxis failure was divided into early (within a month of exposure) and late malaria. Results: Two hundred fifty-two travelers were included in the study. Sixty-two (24.6%) travelers developed malaria, 56 (91.9%) caused by P. vivax, with 54 (87.1%) cases considered as late malaria. Among travelers using atovaquone-proguanil, there were no cases of early P. falciparum or P. vivax malaria. However, 50.0% of atovaquone-proguanil users developed late vivax malaria, as did 46.5% and 43.5% of mefloquine and doxycycline users, respectively; only 2 (1.4%) primaquine users developed late malaria (P < .0001). Conclusions: Short-course atovaquone-proguanil appears to provide causal (liver schizont stage) prophylaxis for P. vivax, but is ineffective against late, hypnozoite reactivation-related attacks. These findings suggest that primaquine should be considered as the chemoprophylactic agent of choice for areas with high co-circulation of P. falciparum and P. vivax.
Subject(s)
Antimalarials/pharmacology , Atovaquone/pharmacology , Malaria, Vivax/prevention & control , Proguanil/pharmacology , Adult , Aged , Antigens, Protozoan , Antimalarials/administration & dosage , Atovaquone/administration & dosage , Drug Combinations , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Proguanil/administration & dosage , Retrospective Studies , Travel , Young AdultABSTRACT
BACKGROUND: We evaluated existing data on the prophylactic efficacy of atovaquone-proguanil (AP) in order to determine whether prophylaxis in travellers can be discontinued on the day of return from a malaria-endemic area instead of seven days after return as per currently recommended post-travel schedule. METHODS: PubMed and Embase databases were searched to identify relevant studies. This PROSPERO-registered systematic review followed PRISMA guidelines. The search strategy included terms or synonyms relevant to AP combined with terms to identify articles relating to prophylactic use of AP and inhibitory and half-life properties of AP. Studies considered for inclusion were: randomized controlled trials, cohort studies, quasi-experimental studies, open-label trials, patient-control studies, cross-sectional studies; as well as case-series and non-clinical studies. Data on study design, characteristics of participants, interventions, and outcomes were extracted. Primary outcomes considered relevant were prophylactic efficacy and prolonged inhibitory activity and half-life properties of AP. RESULTS: The initial search identified 1,482 publications, of which 40 were selected based on screening. Following full text review, 32 studies were included and categorized into two groups, namely studies in support of the current post-travel regimen (with a total of 2,866 subjects) and studies in support of an alternative regimen (with a total of 533 subjects). CONCLUSION: There is limited direct and indirect evidence to suggest that an abbreviated post-travel regimen for AP may be effective. Proguanil, however, has a short half-life and is essential for the synergistic effect of the combination. Stopping AP early may result in mono-prophylaxis with atovaquone and possibly select for atovaquone-resistant parasites. Furthermore, the quality of the studies in support of the current post-travel regimen outweighs the quality of the studies in support of an alternative short, post-travel regimen, and the total sample size of the studies to support stopping AP early comprises a small percentage of the total sample size of the studies performed to establish the efficacy of the current AP regimen. Additional research is required - especially from studies evaluating impact on malaria parasitaemia and clinical illness and conducted among travellers in high malaria risk settings - before an abbreviated regimen can be recommended in current practice. PROSPERO REGISTRATION NUMBER: CRD42017055244.
Subject(s)
Antimalarials/administration & dosage , Atovaquone/administration & dosage , Malaria/drug therapy , Post-Exposure Prophylaxis , Proguanil/administration & dosage , Travel , Drug Administration Schedule , Drug Combinations , Drug Synergism , Endemic Diseases/prevention & control , Humans , Malaria/prevention & control , Travel-Related IllnessABSTRACT
BACKGROUND: Both in endemic countries and in imported malaria, changes in total and differential leukocyte count during Plasmodium falciparum infection have been described. To study the exact dynamics of differential leukocyte counts and their ratios, they were monitored in a group of healthy non-immune volunteers in two separate Controlled Human Malaria Infection (CHMI) studies. METHODS: In two CHMI trials, CHMI-a and CHMI-b, 15 and 24 healthy malaria-naïve volunteers, respectively, were exposed to bites of infected mosquitoes, using the P. falciparum research strain NF54 and the novel clones NF135.C10 and NF166.C8. After mosquito bite exposure, twice-daily blood draws were taken to detect parasitaemia and to monitor the total and differential leukocyte counts. All subjects received a course of atovaquone-proguanil when meeting the treatment criteria. RESULTS: A total of 39 volunteers participated in the two trials. Thirty-five participants, all 15 participants in CHMI-a and 20 of the 24 volunteers in CHMI-b, developed parasitaemia. During liver stage development of the parasite, the median total leukocyte count increased from 5.5 to 6.1 × 109 leukocytes/L (p = 0.005), the median lymphocyte count from 1.9 to 2.2 (p = 0.001) and the monocyte count from 0.50 to 0.54 (p = 0.038). During the subsequent blood stage infection, significant changes in total and differential leukocyte counts lead to a leukocytopenia (nadir median 3.3 × 109 leukocytes/L, p = 0.0001), lymphocytopenia (nadir median 0.7 × 109 lymphocytes/L, p = 0.0001) and a borderline neutropenia (nadir median 1.5 × 109 neutrophils/L, p = 0.0001). The neutrophil to lymphocyte count ratio (NLCR) reached a maximum of 4.0. Significant correlations were found between parasite load and absolute lymphocyte count (p < 0.001, correlation coefficient - 0.46) and between parasite load and NLCR (p < 0.001, correlation coefficient 0.50). All parameters normalized after parasite clearance. CONCLUSIONS: During the clinically silent liver phase of malaria, an increase of peripheral total leukocyte count and differential lymphocytes and monocytes occurs. This finding has not been described previously. This increase is followed by the appearance of parasites in the peripheral blood after 2-3 days, accompanied by a marked decrease in total leukocyte count, lymphocyte count and the neutrophil count and a rise of the NLCR.
Subject(s)
Leukocyte Count , Malaria, Falciparum/parasitology , Parasitemia/parasitology , Plasmodium falciparum/physiology , Antimalarials/administration & dosage , Asymptomatic Infections , Atovaquone/administration & dosage , Drug Combinations , Healthy Volunteers , Humans , Liver/parasitology , Malaria, Falciparum/blood , Parasitemia/blood , Proguanil/administration & dosageABSTRACT
BACKGROUND: To assess the effect on malaria prevalence, village specific monthly administrations of pyrimethamine, chlorproguanil, chloroquine or placebo were given to children in four previously treatment-naïve Liberian villages, 1976-78. Plasmodium falciparum in vivo resistance developed to pyrimethamine only. Selection of molecular markers of P. falciparum resistance after 2 years of treatment are reported. METHODS: Blood samples were collected from 191 study children in a survey in 1978. Polymorphisms in pfcrt, pfmdr1, pfdhfr, pfdhps, pfmrp1 and pfnhe1 genes were determined using PCR-based methods. RESULTS: Pfcrt 72-76 CVIET was found in one chloroquine village sample, all remaining samples had pfcrt CVMNK. Pfmdr1 N86 prevalence was 100%. A pfmdr1 T1069ACTâACG synonymous polymorphism was found in 30% of chloroquine village samples and 3% of other samples (P = 0.008). Variations in pfnhe1 block I were found in all except the chloroquine treated village (P < 0.001). Resistance associated pfdhfr 108N prevalence was 2% in the pyrimethamine village compared to 45-65% elsewhere, including the placebo village (P = 0.001). CONCLUSIONS: Chloroquine treatment possibly resulted in the development of pfcrt 72-76 CVIET. Selection of pfmdr1 T1069ACG and a pfnhe1 block 1 genotypes indicates that chloroquine treatment exerted a selective pressure on P. falciparum. Pyrimethamine resistance associated pfdhfr 108N was present prior to the introduction of any drug. Decreased pfdhfr 108N frequency concurrent with development of pyrimethamine resistance suggests a non-pfdhfr polymorphisms mediated resistance mechanism.
Subject(s)
Antimalarials/administration & dosage , Chloroquine/administration & dosage , Drug Resistance , Plasmodium falciparum/drug effects , Polymorphism, Genetic , Proguanil/analogs & derivatives , Pyrimethamine/administration & dosage , Child , Child, Preschool , Humans , Liberia , Malaria, Falciparum/drug therapy , Plasmodium falciparum/genetics , Polymerase Chain Reaction , Proguanil/administration & dosage , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , Selection, GeneticABSTRACT
BACKGROUND: The UK deployed a task force to Sierra Leone to assist in ending the 2014/15 Ebola outbreak. Malaria protection was based on existing Defence Policy which saw a wide range of bite prevention measures deployed. Atovaquone/Proguanil ("A/P"), Doxycycline ("D") and Mefloquine ("M") were the chemoprophylactic medications that were prescribed. A survey was undertaken to audit the Adverse Effect (AE) burden experienced by the population. METHOD: A questionnaire based survey was administered that sought information on individuals' experiences with malaria chemoprophylaxis. RESULTS: 337 personnel were eligible to take part and 151 (46.3%) individuals returned questionnaires. The reported AE rates for the three drugs were "A/P" 28% of the respondents, "D" 25% and "M" 23.1%. 24 individuals (15.9%) reported 1 AE while 34 (22.5%) reported multiple AEs. Eight (5.3%) individuals changed medication (Five "A/P", two "M" and one "D") because of unacceptable AE but no significant neuro/psychological conditions were reported. The malaria attack rate for the deployed population was 0.4 cases per thousand person weeks which is very low when compared to other military deployments to the West African Area. CONCLUSION: UK Defence policy is effective in the way it balances the risk of malaria with that of AE due to chemoprophylaxis. "M" remains an acceptable chemoprophylactic agent for a section of the population.
Subject(s)
Antimalarials/adverse effects , Chemoprevention/adverse effects , Hemorrhagic Fever, Ebola/epidemiology , Malaria/prevention & control , Military Personnel , Travel , Adult , Antimalarials/administration & dosage , Atovaquone/administration & dosage , Atovaquone/adverse effects , Disease Outbreaks/prevention & control , Disease Outbreaks/statistics & numerical data , Doxycycline/administration & dosage , Doxycycline/adverse effects , Drug Combinations , Hemorrhagic Fever, Ebola/virology , Humans , Malaria/epidemiology , Malaria/parasitology , Mefloquine/administration & dosage , Mefloquine/adverse effects , Proguanil/administration & dosage , Proguanil/adverse effects , Sierra Leone/epidemiology , Surveys and Questionnaires , United KingdomABSTRACT
Background: Malaria carries a high case fatality among patients with sickle cell disease. In Jos University Teaching Hospital, at the time of this study, the use of Proguanil was the acceptable mode of chemoprophylaxis for preventing malaria in these patients. Intermittent Preventive Treatment (IPT) with Sulphadoxine-Pyrimethamine [SP] has shown great potential for reducing the prevalence of malaria and anaemia among pregnant women, infants and travellers. We hypothesised that monthly SP was superior to daily Proguanil in reducing malaria parasitaemia, clinical malaria attacks and sickle cell crises in such patients. Objective: To assess the efficacy and affordability of monthly SP versus daily Proguanil for malaria chemoprophylaxis in patients attending Sickle Cell Clinic at Jos University Teaching Hospital, Plateau State, Nigeria. Methods: One hundred and fifty four patients [114 children and 40 adults] with Sickle Cell Disease in their steady state were randomized to monthly SP or daily Proguanil for malaria chemoprophylaxis. Active detection of malaria parasite in the peripheral blood and packed cell volumes were done at each monthly visit to the clinic over a period of three months. The primary outcome measure was the proportion of patients with malaria parasite in the peripheral blood at the end of 3 months. The secondary outcome measures included episodes of clinical malaria attacks, frequency and type of sickle cell crises and adverse effects of the medication. Results: Ninety four percent [72/77] of patients in the SP group and 91% [70/77] in the Proguanil group respectively completed three months of follow up. SP reduced the prevalence of malaria parasitaemia by 25% [(14%) 10/72] compared to 6.4% [(30%) 21/70] in the proguanil group. [X2 54; p = 0.01]. Seventeen percent [12/72] of the patients receiving monthly SP had malaria attacks compared to 57% [40/70] on prophylaxis with Proguanil. [X2 =25; p< 0.0003]. Thirty three percent [24/72] of the patients receiving SP had at least an episode of bone pain crises compared to 69% [48/70] of the patients receiving Proguanil. [X2 =17.6; p<0.0001]. SP was 8 times cheaper than Proguanil. Conclusion: Monthly chemoprophylaxis with SP was more efficacious than daily Proguanil in reducing the prevalence of asymptomatic malaria parasitaemia, clinical malaria attack and sickle cell crises in patients with sickle cell disease. SP was 8 times cheaper than Proguanil. No significant side effect was recorded in both groups. The current practice of routinely prescribing daily Proguanil to SCD patients for malaria chemoprophylaxis needs to be reviewed.
Subject(s)
Anemia, Sickle Cell/drug therapy , Antimalarials/administration & dosage , Malaria/prevention & control , Proguanil/administration & dosage , Pyrimethamine/administration & dosage , Sulfadoxine/administration & dosage , Adult , Anemia, Sickle Cell/complications , Chemoprevention , Drug Administration Schedule , Drug Combinations , Female , Humans , Infant , Malaria/complications , Male , Nigeria , Parasitemia/epidemiology , Parasitemia/prevention & control , Pregnancy , Treatment OutcomeABSTRACT
Canine babesiosis is a severe and potentially life threatening infection. In Europe, Babesia canis is considered to be the most common species responsible for the disease. We report two cases of babesiosis caused by Babesia gibsoni. The polymerase chain reaction, restriction fragment length polymorphism analysis and further sequencing of 18S rRNA gene fragments from blood samples of both dogs revealed the identity of isolates with B. gibsoni genotypes from other dogs worldwide. This species was previously not known to infect dogs in Slovakia. It is resistant to traditional anti-babesial therapy. Therefore, correct diagnosis is crucial for the successful treatment, especially in dogs with hemolytic anemia and febrile conditions.
Subject(s)
Babesia/isolation & purification , Babesiosis/parasitology , Dog Diseases/parasitology , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antimalarials/administration & dosage , Antimalarials/therapeutic use , Atovaquone/administration & dosage , Atovaquone/therapeutic use , Azithromycin/administration & dosage , Azithromycin/therapeutic use , Babesia/classification , Babesiosis/drug therapy , Babesiosis/epidemiology , Dog Diseases/drug therapy , Dog Diseases/epidemiology , Dogs , Drug Combinations , Genotype , Male , Proguanil/administration & dosage , Proguanil/therapeutic use , Slovakia/epidemiologyABSTRACT
BACKGROUND: Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the effects of G6PD status on hemolysis in children treated with Intermittent Preventive Treatment in infants (IPTi) antimalarial regimens. We sought to examine the joint effects of G6PD status and IPTi antimalarial treatment on incidence of hemolysis in asymptomatic children treated with CD, sulfadoxine-pyrimethamine (SP), and mefloquine (MQ). METHODS: A secondary analysis of data from a double-blind, placebo-controlled trial of IPTi was conducted. Hemoglobin (Hb) measurements were made at IPTi doses, regular follow-up and emergency visits. G6PD genotype was determined at 9 months looking for SNPs for the A- genotype at coding position 202. Multivariable linear and logistic regression models were used to examine hemolysis among children with valid G6PD genotyping results. Hemolysis was defined as the absolute change in Hb or as any post-dose Hb <8 g/dL. These outcomes were assessed using either a single follow-up Hb on day 7 after an IPTi dose or Hb obtained 1 to 14 or 28 days after each IPTi dose. FINDINGS: Relative to placebo, CD reduced Hb by approximately 0.5 g/dL at day 7 and within 14 days of an IPTi dose, and by 0.2 g/dL within 28 days. Adjusted declines in the CD group were larger than in the MQ and SP groups. At day 7, homo-/hemizygous genotype was associated with higher odds of Hb <8 g/dL (adjusted odds ratio = 6.7, 95% CI 1.7 to 27.0) and greater absolute reductions in Hb (-0.6 g/dL, 95% CI -1.1 to 0.003). There was no evidence to suggest increased reductions in Hb among homo-/hemizygous children treated with CD compared to placebo, SP or MQ. CONCLUSIONS: While treatment with CD demonstrated greater reductions in Hb at 7 and 14 days after an IPTi dose compared to both SP and MQ, there was no evidence that G6PD deficiency exacerbated the adverse effects of CD, despite evidence for higher hemolysis risk among G6PDd infants.
Subject(s)
Dapsone/administration & dosage , Glucosephosphate Dehydrogenase Deficiency/genetics , Hemolysis/drug effects , Malaria/drug therapy , Mefloquine/administration & dosage , Proguanil/analogs & derivatives , Pyrimethamine/administration & dosage , Sulfadoxine/administration & dosage , Antimalarials/administration & dosage , Antimalarials/therapeutic use , Cohort Studies , Dapsone/adverse effects , Dapsone/therapeutic use , Double-Blind Method , Drug Combinations , Female , Genotype , Glucosephosphate Dehydrogenase/genetics , Glucosephosphate Dehydrogenase Deficiency/metabolism , Hemoglobins/analysis , Humans , Infant , Logistic Models , Malaria/prevention & control , Male , Mefloquine/therapeutic use , Multivariate Analysis , Odds Ratio , Poisson Distribution , Polymorphism, Single Nucleotide , Proguanil/administration & dosage , Proguanil/adverse effects , Proguanil/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , TanzaniaSubject(s)
Atovaquone/administration & dosage , Carotid Artery Diseases , Fever , Headache , Intracranial Aneurysm , Malaria, Falciparum , Plasmodium falciparum , Proguanil/administration & dosage , Adult , Antimalarials/administration & dosage , Carotid Artery Diseases/diagnosis , Carotid Artery Diseases/surgery , Carotid Artery, Internal/diagnostic imaging , Chemoprevention/methods , Cote d'Ivoire/epidemiology , Diagnosis, Differential , Drug Combinations , Female , Fever/blood , Fever/diagnosis , Fever/drug therapy , Fever/etiology , Headache/diagnosis , Headache/etiology , Humans , Intracranial Aneurysm/diagnosis , Intracranial Aneurysm/surgery , Magnetic Resonance Imaging/methods , Malaria, Falciparum/diagnosis , Malaria, Falciparum/drug therapy , Malaria, Falciparum/epidemiology , Malaria, Falciparum/physiopathology , Neurosurgical Procedures/methods , Plasmodium falciparum/drug effects , Plasmodium falciparum/isolation & purification , Tomography, X-Ray Computed/methods , Treatment OutcomeABSTRACT
Clinical failure of Malarone™ chemoprophylaxis is extremely rare. We report a case of Plasmodium falciparum malaria in a returned traveler to Ghana who fully adhered to atovaquone-proguanil (Malarone™) chemoprophylaxis daily dosing, yet took the pills on an empty stomach. Screening of the P. falciparum isolate revealed triple codon mutation of Dhfr at positions 51, 59, and 108. Plasma drug levels of both atovaquone and proguanil revealed sub-therapeutic concentrations.
Subject(s)
Antimalarials/administration & dosage , Atovaquone/administration & dosage , Malaria, Falciparum/prevention & control , Proguanil/administration & dosage , Travel , Adult , Antimalarials/blood , Atovaquone/blood , Codon , Drug Combinations , Drug Resistance/genetics , Female , Ghana , Humans , Malaria, Falciparum/parasitology , Mutation , Plasmodium falciparum/genetics , Polymorphism, Single Nucleotide , Proguanil/blood , Sequence Analysis, DNA , Tetrahydrofolate Dehydrogenase/genetics , Treatment FailureABSTRACT
BACKGROUND: Artemisinin resistance is a major threat to current efforts to eliminate Plasmodium falciparum malaria which rely heavily on the continuing efficacy of artemisinin combination therapy (ACT). It has been suggested that ACT should not be used in mass drug administration (MDA) in areas where artemisinin-resistant P. falciparum is prevalent, and that atovaquone-proguanil (A-P) might be a preferable alternative. However, a single point mutation in the cytochrome b gene confers high level resistance to atovaquone, and such mutant parasites arise frequently during treatment making A-P a vulnerable tool for elimination. METHODS: A deterministic, population level, mathematical model was developed based on data from Cambodia to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for mass drug administration and/or treatment of P. falciparum malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination. RESULTS: The model showed the initial efficacy of ACT and A-P for MDA to be similar. However, each round of A-P MDA resulted in rapid acquisition and spread of atovaquone resistance. Even a single round of MDA could compromise efficacy sufficient to preclude its use for treatment or prophylaxis. A switch to A-P for treatment of symptomatic episodes resulted in a complete loss of efficacy in the population within four to five years of its introduction. The impact of MDA was temporary and a combination of maintained high coverage with ACT treatment for symptomatic individuals and LLIN was necessary for elimination. CONCLUSION: For malaria elimination, A-P for MDA or treatment of symptomatic cases should be avoided. A combined strategy of high coverage with ACT for treatment of symptomatic episodes, LLIN and ACT + P MDA would be preferable.
Subject(s)
Antimalarials/administration & dosage , Atovaquone/administration & dosage , Malaria, Falciparum/drug therapy , Models, Biological , Proguanil/administration & dosage , Drug Combinations , Drug Resistance , Humans , Insecticide-Treated Bednets , Plasmodium falciparumABSTRACT
The efficacy of Malarone(®) alone and in combination with doxycycline (DOXY) against Babesia gibsoni infections was examined in 8 dogs. In all dogs except one treated with Malarone(®), parasitemia decreased, and anemia improved soon after initiation of treatment. However, 3 of 4 dogs treated with Malarone(®) relapsed, and relapse was inhibited in 2 of 4 dogs treated with Malarone(®) and DOXY. All relapsed dogs responded well to the second treatment, but 1 dog relapsed again and did not respond to the third treatment. Malarone(®) may be useful for acute stage of B. gibsoni infections, and at least second repeating treatment might be effective.